J. W. Marks

发表

Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes.

M. Rosenblum, Y. Mackeyev, L. Wilson, 2005, The journal of physical chemistry. B.

Fullerene (C60) Immunoconjugates: Interaction of Water‐Soluble C60 Derivatives with the Murine anti‐gp240 Melanoma Antibody.

R. Weisman, D. Tsyboulski, M. Rosenblum, 2006 .

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

Johannes Waltenberger, Philip Thorpe, Lawrence Cheung, 2002, Proceedings of the National Academy of Sciences of the United States of America.

CLOUDS , a protocol for deriving a molecular proton density via NMR

S. Ran, J. Waltenberger, J. W. Marks, 2002 .

The TWEAK Receptor Fn14 is a Novel Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment

W. Hittelman, M. Rosenblum, N. Tran, 2012, The Journal of investigative dermatology.

Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.

F. Malavasi, M. Rosenblum, K. Mehta, 2004, Molecular cancer therapeutics.

Preclinical Development Single-Chain Antibody-Based Immunotoxins Targeting Her 2 / neu : Design Optimization and Impact of Af fi nity on Antitumor Ef fi cacy and Off-Target Toxicity

Yu Cao, C. Xiong, G. Adams, 2011 .

Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

C. Xiong, Chun Xing Li, G. Adams, 2011, Molecular Cancer Therapeutics.

Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

M. Rosenblum, L. Wilson, R. D. Bolskar, 2011, Translational oncology.

Recombinant single‐chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor

M. Rosenblum, Yuying Liu, J. W. Marks, 2004, International journal of cancer.

Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells

W. Hittelman, M. Rosenblum, J. Winkles, 2011, Molecular Cancer Therapeutics.

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin

M. Rosenblum, J. W. Marks, L. Cheung, 1999, Cancer Chemotherapy and Pharmacology.

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Yu Cao, J. Marks, M. Rosenblum, 2009, Cancer research.

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Yu Cao, J. Marks, M. Rosenblum, 2009, Cancer research.

Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.

M. Rosenblum, Yuying Liu, J. W. Marks, 2003, Cancer research.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

B. Aggarwal, K. Ahn, W. Hittelman, 2012, Biochemical pharmacology.

Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160

D. Hamer, James E. Robinson, S. Pincus, 2016, Journal of Virology.

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.

R. Aguiar, B. Aggarwal, K. Ahn, 2010, Neoplasia.

Aptamer:toxin conjugates that specifically target prostate tumor cells.

Andrew D Ellington, Laura A Lavery, M. Levy, 2006, Cancer research.

The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.

R. Aguiar, B. Aggarwal, B. Sung, 2010, Biochemical pharmacology.

Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.

M. Rosenblum, J. W. Marks, L. Cheung, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

W. Hittelman, M. Rosenblum, Yuying Liu, 2012, Cancer letters.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

R. Aguiar, W. Hittelman, M. Rosenblum, 2007, Molecular Cancer Therapeutics.

Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody.

R. Weisman, D. Tsyboulski, M. Rosenblum, 2006, Chemical communications.

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies

W. Hittelman, M. Rosenblum, J. W. Marks, 2014, Oncogene.

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu

W. Hittelman, M. Rosenblum, J. W. Marks, 2013, Molecular Cancer Therapeutics.

Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells

W. Hittelman, M. Rosenblum, J. Winkles, 2011, Molecular Cancer Therapeutics.

A gelonin-containing immunotoxin directed against human breast carcinoma.

M. Rosenblum, J. W. Marks, J. Rotbein, 1992, Molecular biotherapy.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

R. Aguiar, W. Hittelman, M. Rosenblum, 2007, Molecular Cancer Therapeutics.

Curative surgical resection following reirradiation for recurrent rectal cancer.

J. Marks, M. Mohiuddin, J. W. Marks, 1997, International journal of radiation oncology, biology, physics.

Cited Articles Citing Articles E-mail Alerts Design, Expression, Purification, and Characterization, in Vitro and in Vivo, of an Antimelanoma Single-chain Fv Antibody Fused to the Toxin Gelonin

M. Rosenblum, Yuying Liu, J. W. Marks, 2022 .